1. State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
- Author
-
Frankhouser, David E, Rockne, Russell C, Uechi, Lisa, Zhao, Dandan, Branciamore, Sergio, O’Meally, Denis, Irizarry, Jihyun, Ghoda, Lucy, Ali, Haris, Trent, Jeffery M, Forman, Stephen, Fu, Yu-Hsuan, Kuo, Ya-Huei, Zhang, Bin, and Marcucci, Guido
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Genetics ,Rare Diseases ,Clinical Research ,Cancer ,Hematology ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Mice ,Animals ,Transcriptome ,Fusion Proteins ,bcr-abl ,Protein Kinase Inhibitors ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Tetracyclines ,Drug Resistance ,Neoplasm ,Clinical Sciences ,Immunology ,Cardiovascular medicine and haematology ,Clinical sciences ,Oncology and carcinogenesis - Abstract
Chronic myeloid leukemia (CML) is initiated and maintained by BCR::ABL which is clinically targeted using tyrosine kinase inhibitors (TKIs). TKIs can induce long-term remission but are also not curative. Thus, CML is an ideal system to test our hypothesis that transcriptome-based state-transition models accurately predict cancer evolution and treatment response. We collected time-sequential blood samples from tetracycline-off (Tet-Off) BCR::ABL-inducible transgenic mice and wild-type controls. From the transcriptome, we constructed a CML state-space and a three-well leukemogenic potential landscape. The potential's stable critical points defined observable disease states. Early states were characterized by anti-CML genes opposing leukemia; late states were characterized by pro-CML genes. Genes with expression patterns shaped similarly to the potential landscape were identified as drivers of disease transition. Re-introduction of tetracycline to silence the BCR::ABL gene returned diseased mice transcriptomes to a near healthy state, without reaching it, suggesting parts of the transition are irreversible. TKI only reverted the transcriptome to an intermediate disease state, without approaching a state of health; disease relapse occurred soon after treatment. Using only the earliest time-point as initial conditions, our state-transition models accurately predicted both disease progression and treatment response, supporting this as a potentially valuable approach to time clinical intervention, before phenotypic changes become detectable.
- Published
- 2024